The device used to manufacture an immunotherapeutic agent is a highly relevant factor in ensuring the most optimal product in terms of the time it takes to produce a dose of the therapy, the risk encountered in processing, and the final quality of that product. Three types of devices for T cell expansion were compared: a static culture perfusion membrane platform (SCPM), a rocking bag device (RB), and two sizes of hollow-fiber perfusion bioreactor (HFB-Large and HFB-Small). The T cell yield, time to dose, fold-expansion (FE), open events (OE), and Hands on Time (HoT) required for each device were measured.